F-1/A: I Bella Perfect Inc. Files for Nasdaq IPO

I Bella Perfect Inc. has filed an amended registration statement for its initial public offering, aiming to list on the Nasdaq Capital Market.

Summary

• I Bella Perfect Inc., a British Virgin Islands company operating aesthetic medical clinics in Malaysia through its subsidiaries, has filed an amended registration statement (F-1/A) for its initial public offering (IPO).
• The company plans to offer 3,750,000 Class A Ordinary Shares, with an estimated IPO price range of $4.00 to $6.00 per share.
• The net proceeds from the offering are intended for establishing new clinics, marketing expenses, purchasing new medical equipment, and working capital.
• The company has applied to list its Class A Ordinary Shares on the Nasdaq Capital Market under the symbol 'IBL'.
• The filing highlights a dual-class share structure with Class B shares having 20 votes per share, potentially limiting shareholder influence.
• Key management and major shareholders will retain significant voting control post-offering.
• The company is identified as an 'emerging growth company' and a 'foreign private issuer', allowing for reduced reporting requirements.
• The company has identified material weaknesses in internal controls related to IFRS and SEC reporting knowledge and a lack of formal accounting policies and procedures.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic filing, with strong market growth potential and a clear business model, but tempered by identified internal control weaknesses and the risks associated with a dual-class share structure and concentrated ownership.

Positives

• The company operates in the growing aesthetic medicine market in Malaysia, which is projected to grow at a CAGR of 9.2% from 2025 to 2029.
• I Bella Perfect has a strong brand reputation and emphasizes quality treatment and high service quality, with positive customer reviews.
• The company has experienced and highly skilled medical professionals, with LCP-certified physicians and ongoing training.
• Revenue increased by 22.7% from FY2024 to FY2025, driven by the opening of new clinics and increased aesthetic medical services.
• Gross profit margin improved from 64.0% in FY2024 to 66.3% in FY2025, attributed to a strategic shift towards higher-margin services.
• The company has a clear growth strategy focused on expanding operations, its medical team, and purchasing new equipment.

Negatives

• The company depends significantly on a limited number of LCP-certified aesthetic physicians, and a shortage could impact operations and growth.
• The company operates in a heavily regulated industry and faces ongoing compliance costs and potential penalties for non-compliance.
• Material weaknesses in internal control over financial reporting have been identified, including a lack of sufficient skilled staff and formal accounting policies.
• The dual-class share structure may limit shareholder influence and could discourage change-of-control transactions beneficial to Class A shareholders.
• Ownership will remain concentrated in the hands of major shareholders, potentially limiting minority shareholder influence.
• The company does not intend to pay dividends for the foreseeable future.
• The company may be excluded from certain stock indices due to its dual-class share structure, potentially affecting investor attractiveness.
• There is a risk of difficulty in enforcing judgments against the company due to its BVI incorporation and operations primarily in Malaysia.
• The company has identified material weaknesses in internal controls, including a lack of skilled staff with IFRS and SEC reporting knowledge and a lack of formal accounting policies and procedures.

Risks

• Dependence on brand and reputation; damage could materially impact business.
• Conducting business in a heavily regulated industry with ongoing compliance costs and penalties for non-compliance.
• Internal control system and compliance team may not prevent all possible non-compliance incidents.
• Subject to customer complaints, claims, and legal proceedings that could affect brand image and results.
• Inability to recruit and retain adequate managers, doctors, and support staff could harm service quality and business.
• Physicians and medical professionals may not obtain or maintain appropriate licenses, leading to penalties.
• Failure to maintain the quality of cosmetics, treatment equipment, and skincare products could lead to liabilities and reputational damage.
• Reliance on a limited number of suppliers for medical materials and equipment.
• Unfavorable market perception of the aesthetic medicine industry could adversely affect business.
• Intense competition from existing and new players, including unlicensed centers.
• Inability to adapt to changing aesthetic medical trends and customer needs.
• Revenue sensitivity to changes in local and global economic conditions and customer disposable income.
• Geopolitical conflicts may adversely affect global economic conditions and the trading price of shares.
• Failure to manage growth effectively could hinder business and financial results.
• Newly opened or acquired clinics may not achieve anticipated operating results, potentially leading to revenue cannibalization.
• Inability to obtain sufficient funding for growth strategies could adversely affect business prospects.
• Historical financial and operating results may not be indicative of future performance.
• Risks related to management of customer medical data and potential security breaches.
• Technological failures or security breaches of IT systems could disrupt business operations.
• Significant advertising and marketing expenses may not be effective and could adversely affect results.
• Dependence on the quality, effectiveness, and safety of products, including those manufactured by OEMs.
• Reliance on third-party manufacturers for skincare products.
• Potential for significant liability claims, complaints, litigation, and regulatory investigations related to safety and adverse publicity.
• Recent changes to Nasdaq listing standards and expanded discretionary authority may make it more difficult to qualify for or maintain a listing.
• Concentrated share ownership by largest shareholders may limit ability to influence corporate matters.
• As a controlled company, I Bella Perfect may elect to rely on exemptions from certain corporate governance requirements.
• The dual-class share structure may adversely affect the value and liquidity of Class A Ordinary Shares.
• There has been no public market for Class A Ordinary Shares prior to this offering, and resale may be difficult.
• Immediate and substantial dilution in net tangible book value for investors purchasing shares in the offering.
• Failure to implement and maintain effective internal controls could lead to reporting failures, fraud, and negatively impact investor confidence and share price.
• Incurring substantial increased costs as a result of being a public company.
• Substantial future sales of Class A Ordinary Shares or the anticipation thereof could cause the price to decline.
• Techniques employed by short sellers may drive down the market price.
• The market price of Class A Ordinary Shares may be volatile or decline regardless of operating performance.
• If securities or industry analysts do not publish research or reports, or publish negative reports, the price and trading volume could decline.
• The laws of the BVI may not provide shareholders with benefits comparable to those provided by U.S. jurisdictions.
• Difficulty in enforcing judgments against the company.
• Potential difficulty in presenting proposals before annual general meetings or extraordinary general meetings not called by shareholders.
• Recently introduced economic substance legislation of the BVI may adversely impact operations.
• Potential classification as a Passive Foreign Investment Company (PFIC) could have adverse U.S. federal income tax consequences for U.S. Holders.
• Pre-IPO shareholders may be able to sell shares after the offering, potentially impacting the trading price.
• The company's ability to satisfy Nasdaq Capital Market listing requirements could impact its securities' liquidity and price.

Future Outlook

The company expects the aesthetic medicine market in Malaysia to grow at a CAGR of 9.2% from RM949.2 million in 2025 to RM1.47 billion in 2029, driven by population growth, rising disposable income, social media influence, and technological advancements. The company plans to expand its operations by establishing four new clinics within two years of the IPO, strengthen its medical team, and purchase new medical machines and equipment.

Management Comments

• The company believes its competitive strengths include an experienced and highly skilled team of medical professionals, strict safety and quality control, quality treatment, and high service quality.
• Management intends to grow the business through expansion of operations, expansion of the aesthetic medical team, and purchase of new medical machines and equipment.

Industry Context

StockSavvy.ai notes that I Bella Perfect operates in the Malaysian aesthetic medicine market, which is experiencing robust growth driven by increasing consumer interest in self-care and appearance enhancement. The market is characterized by a growing demand for non-invasive and minimally invasive procedures, a trend that aligns with I Bella Perfect's service offerings. However, the industry faces challenges such as a shortage of LCP-certified aesthetic physicians and increasing costs of advanced medical devices. Stricter regulations are also being implemented to ensure safety and quality, which could benefit compliant operators like I Bella Perfect in the long run.

Comparison to Industry Standards

• The company's revenue of RM15.2 million for the fiscal year ended March 31, 2024, represented approximately 1.9% of the Malaysian medical aesthetic market size of RM818.3 million for 2024.
• The company's gross profit margin of 66.3% for FY2025 is a positive indicator compared to industry averages, though specific industry benchmarks for gross margins in aesthetic clinics were not provided in the filing.
• The company's customer repeat rates (ranging from 27.67% to 41.78% for the six months ended Sep 30, 2025) indicate a degree of customer loyalty, which is a key factor in service-based industries.
• The company's reliance on LCP-certified physicians is a critical factor, as Malaysia has a limited pool of approximately 996 such physicians serving 539 private aesthetic clinics as of August 2025, indicating a physician-to-clinic ratio of about 2:1.

Corporate Governance

Legal Proceedings

• An Industrial Court case (No. 18/4-111/26) was filed by a former doctor alleging wrongful dismissal, but the parties reached a settlement and the case was withdrawn.
• The company may become party to other legal or administrative proceedings in the ordinary course of business, including those related to intellectual property, contract breaches, labor claims, and customer complaints.

Related Party Transactions

• Advances and lease payments involving Yen Tsing Then (CEO, Director, Chairperson) and Arrow Peak Sdn Bhd (shareholder controlled by Poh Mei Lai).
• Lease payments for service outlets involving a Director and a related party, where the legal title of one leased property is held in trust by a Director for the related party.
• Dividends paid to original shareholders prior to the reorganization.

Stakeholder Impact

• Shareholders purchasing Class A Ordinary Shares in the IPO may experience immediate dilution in net tangible book value.
• The dual-class share structure and concentrated ownership may limit the ability of Class A shareholders to influence corporate matters.
• Potential investors should be aware of the reduced corporate governance protections available to foreign private issuers and controlled companies.
• Employees are subject to standard Malaysian labor laws and social security contributions.
• Customers may benefit from the company's focus on quality treatment and service, but also face risks related to the aesthetic medicine industry.

Next Steps

• Obtain final approval from Nasdaq for the listing application.
• Complete the initial public offering.
• Utilize net proceeds for establishing new aesthetic medical clinics, marketing expenses, purchasing new medical machines and equipment, and working capital.
• Implement remedial measures to address identified material weaknesses in internal controls.
• Continue to recruit and train aesthetic medical professionals and support staff.
• Expand operations by establishing four new aesthetic medical clinics within two years of the IPO.

Key Dates

Recommendation

The company operates in a growing market with a solid business model and positive revenue trends. However, the identified material weaknesses in internal controls, the concentrated ownership structure, and the potential for limited shareholder influence due to the dual-class share system warrant a cautious approach. While the IPO presents an opportunity for growth, these factors suggest a 'hold' recommendation until the company demonstrates sustained improvement in its internal controls and corporate governance practices.

Keywords

I Bella Perfect Inc., IPO, Nasdaq listing, Aesthetic medical services, Malaysia, Registration Statement, F-1/A, Class A Ordinary Shares, Dual-class shares, Controlled company, Emerging growth company, Foreign private issuer, Internal controls, Beauty industry